

## Special Issue

# Basic Research of Hepatopancreatobiliary Tumor

### Message from the Guest Editors

Over the past several decades, primary liver cancer (PLC), pancreatic cancer, and gallbladder cancer have become the focus of rising concern mainly due to the increasing rates of incidence and high global mortality. Today, the tumor microenvironment appears to be highly involved in the tumor pathological condition and poor prognosis. There has been no major breakthrough in drug treatment for hepatopancreatobiliary tumor in recent 10 years. Recently, diversity and heterogeneity in the tumor microenvironment have attracted attention. New technology developments bring more opportunities for scientists to understand tumor heterogeneity and new therapy. To summarize, we focus on basic research in hepatobiliary and pancreatic tumors. Original research articles and reviews are welcome in this Special Issue. We aim to study the mechanisms of hepatopancreatobiliary tumors. Research areas may include (but are not limited to) the following: tumorigenesis, tumor proliferation, tumor therapy target, tumor drug resistance, tumor metabolism, and the tumor immune microenvironment.

---

### Guest Editors

Prof. Dr. Lianxin Liu

Prof. Dr. Yingbin Liu

Prof. Dr. Paul J. Chiao

---

### Deadline for manuscript submissions

closed (5 May 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/164110](https://mdpi.com/si/164110)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)